Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ACYCLOVIR

All products: not a benefit

Other products in the same Health Canada class (D06B, D06BB) — coverage varies; not interchangeable

  • Imiquimod (Taro-Imiquimod Pump): not a benefit
  • Metronidazole (Noritate): general benefit, Not a benefit
  • Silver sulfadiazine (Flamazine): general benefit

Apo-Acyclovir Ointment · DIN 02477130 · 5% · Top Oint

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Acyclovir Ointment · DIN 02477130 Manufacturer: Apotex Inc.; listing date 2019-05-31 Health Canada: Marketed since 2019-03-14 · brand APO-ACYCLOVIR OINTMENT · ATC D06BB03 ACICLOVIR · form Ointment · route Topical · ingredients ACYCLOVIR 5 %/W/W · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96789 · Verify on the e-Formulary ↗ (DIN 02477130)

Source record
DIN 02477130: Apo-Acyclovir Ointment Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840406002; group id 816; item number 1995; lccId None; manufacturer id APX Source form: Top Oint; strength: 5% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $12.3114; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477130 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96789
Interchangeable products
Taro-Acyclovir · DIN 02522306 · not recorded Zovirax · DIN 00569771 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS) and how they are covered

Matched class: 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, DIMETHICONE., FLUOROURACIL, FUSIDIC ACID, HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE & TAZAROTENE, ISOPROPYL MYRISTATE, ISOTRETINOIN, METRONIDAZOLE & NYSTATIN, MICONAZOLE NITRATE, MOMETASONE FUROATE, MUPIROCIN CALCIUM, PERMETHRIN, PYRETHRINS & PIPERONYL BUTOXIDE, SILVER SULFADIAZINE, SODIUM FUSIDATE, TERBINAFINE HCL, ZINC SULFATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, CLOTRIMAZOLE, COLLAGENASE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, KETOCONAZOLE, METRONIDAZOLE, MUPIROCIN, NYSTATIN, TERCONAZOLE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

HALOBETASOL PROPIONATE & TAZAROTENE

· 1 products · General benefit · strengths: 0.01% & 0.045% · Lot

BIMEKIZUMAB

· 4 products · Limited Use, codes 641 · strengths: 160mg/mL, 320mg/2mL · Inj Sol-1mL Pref Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-2mL Pref Autoinj (Preservative-Free), Inj Sol-2mL Pref Syr (Preservative-Free)

GUSELKUMAB

· 2 products · Limited Use, codes 658 · strengths: 100mg/mL · Inj Sol-1mL Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free)

TAZAROTENE

· 1 products · Limited Use, codes 636 · strengths: 0.045% w/w · Lot

TILDRAKIZUMAB

· 1 products · Limited Use, codes 629 · strengths: 100mg/mL · Inj Sol-1mL Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:00 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04 and 53 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Zovirax (acyclovir 5%) cream is indicated for the topical management of initial episodes of genital herpes simplex infections. The prophylactic use of this preparation has not been established. Zovirax (acyclovir 5%) ointment is for the management of initial episodes of genital herpes simplex infections. It is also indicated in the management of non-life-threatening cutaneous herpes simplex virus infections in immunocompromised patients. The prophylactic use of this preparation has not been established. Pr ZOVIRAX ® Product Monograph Page 2 of 32 In the treatment of genital herpes, appropriate examinations should be performed to rule out other sexually transmitted diseases. Therapy should begin as early as possible after the start of an infection. Whereas cutaneous lesions associated with herpes simplex infections are often pathognomonic, TZANCK smears prepared from lesion exudate or scrapings may assist in the diagnosis. Positive cultures for herpes simplex virus offer the only absolute means for confirmation of the diagnosis. These indications are based on … https://pdf.hres.ca/dpd_pm/00059349.PDF PM date: December 22, 2020 Source product: ZOVIRAX; DIN 00569771; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Apo-Acyclovir Ointment: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026